1. Home
  2. STTK vs SER Comparison

STTK vs SER Comparison

Compare STTK & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • SER
  • Stock Information
  • Founded
  • STTK 2016
  • SER 2017
  • Country
  • STTK United States
  • SER United States
  • Employees
  • STTK N/A
  • SER N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • SER Biotechnology: Pharmaceutical Preparations
  • Sector
  • STTK Health Care
  • SER Health Care
  • Exchange
  • STTK Nasdaq
  • SER Nasdaq
  • Market Cap
  • STTK 37.6M
  • SER 56.5M
  • IPO Year
  • STTK 2020
  • SER 2018
  • Fundamental
  • Price
  • STTK $0.83
  • SER $6.15
  • Analyst Decision
  • STTK Hold
  • SER Strong Buy
  • Analyst Count
  • STTK 4
  • SER 1
  • Target Price
  • STTK $3.00
  • SER $11.00
  • AVG Volume (30 Days)
  • STTK 423.3K
  • SER 10.3K
  • Earning Date
  • STTK 07-31-2025
  • SER 08-08-2025
  • Dividend Yield
  • STTK N/A
  • SER N/A
  • EPS Growth
  • STTK N/A
  • SER N/A
  • EPS
  • STTK N/A
  • SER N/A
  • Revenue
  • STTK $4,606,000.00
  • SER $51,000.00
  • Revenue This Year
  • STTK N/A
  • SER N/A
  • Revenue Next Year
  • STTK N/A
  • SER N/A
  • P/E Ratio
  • STTK N/A
  • SER N/A
  • Revenue Growth
  • STTK 69.65
  • SER N/A
  • 52 Week Low
  • STTK $0.69
  • SER $3.81
  • 52 Week High
  • STTK $4.99
  • SER $11.57
  • Technical
  • Relative Strength Index (RSI)
  • STTK 38.86
  • SER 51.44
  • Support Level
  • STTK $0.75
  • SER $5.27
  • Resistance Level
  • STTK $0.85
  • SER $5.99
  • Average True Range (ATR)
  • STTK 0.09
  • SER 0.43
  • MACD
  • STTK -0.01
  • SER -0.04
  • Stochastic Oscillator
  • STTK 9.59
  • SER 60.03

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

Share on Social Networks: